Site icon Hot Paths

Biohaven down 5% as spinal muscular atrophy asset misses primary endpoint

Press Room
SMA, spinal muscular atrophy, Written on wooden blocks, a rare disease in which, due to a genetic defect, neurons in the spinal cord responsible for muscle contraction and relaxation gradually die.

Andrzej Rostek

  • Biohaven (NYSE:BHVN) is down ~5% Monday morning after results from a phase 3 trial of taldefgrobep alpha, its candidate for spinal muscular atrophy, failed to show a statistically significant difference vs. placebo in its primary outcome compared to placebo.
  • Results
Exit mobile version